$122.39 Million in Sales Expected for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) This Quarter

Equities research analysts expect Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) to report $122.39 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings. The lowest sales estimate is $122.08 million and the highest is $122.70 million. Eagle Pharmaceuticals posted sales of $41.25 million during the same quarter last year, which suggests a positive year-over-year growth rate of 196.7%. The business is scheduled to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year sales of $417.20 million for the current financial year, with estimates ranging from $407.80 million to $426.60 million. For the next year, analysts expect that the company will report sales of $278.21 million, with estimates ranging from $269.80 million to $286.63 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRXGet Rating) last issued its earnings results on Monday, March 7th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.89). Eagle Pharmaceuticals had a negative return on equity of 4.62% and a negative net margin of 5.03%. The company had revenue of $42.32 million during the quarter, compared to analyst estimates of $47.32 million. During the same period in the previous year, the company posted $0.60 earnings per share.

EGRX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $57.00 price target on the stock in a research report on Monday, March 14th. StockNews.com assumed coverage on Eagle Pharmaceuticals in a research report on Thursday, March 31st. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $54.00.

Several institutional investors and hedge funds have recently added to or reduced their stakes in EGRX. Cutler Group LP bought a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at about $40,000. C M Bidwell & Associates Ltd. bought a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at about $48,000. Point72 Hong Kong Ltd bought a new position in shares of Eagle Pharmaceuticals in the 4th quarter valued at about $62,000. PNC Financial Services Group Inc. grew its holdings in Eagle Pharmaceuticals by 36.2% during the third quarter. PNC Financial Services Group Inc. now owns 1,144 shares of the specialty pharmaceutical company’s stock worth $63,000 after purchasing an additional 304 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in Eagle Pharmaceuticals by 11.5% during the fourth quarter. Lazard Asset Management LLC now owns 2,405 shares of the specialty pharmaceutical company’s stock worth $122,000 after purchasing an additional 248 shares during the period. 88.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EGRX opened at $43.68 on Friday. Eagle Pharmaceuticals has a 1 year low of $36.48 and a 1 year high of $58.25. The stock has a 50 day simple moving average of $48.40 and a 200-day simple moving average of $49.11. The stock has a market cap of $554.60 million, a PE ratio of -65.19 and a beta of 0.68.

About Eagle Pharmaceuticals (Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Recommended Stories

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.